University of Michigan Comprehensive Cancer Center Support Grant

密歇根大学综合癌症中心支持补助金

• 批准号: 8549115
• 负责人: MAX S. WICHA
• 金额: $ 580.13万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-06-01 至 2017-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8549115
• 关键词: Academic Medical Centers; Advanced Malignant Neoplasm; Area; Award; Basic Cancer Research; Basic Science; Beds; Behavioral; Behavioral Research; Bioinformatics; Biological Assay; Biological Factors; Biological Markers; Biotechnology; Breast; Cancer Center; Cancer Center Support Grant; Cell Line; Cellular biology; Clinic; Clinical; Clinical Investigator; Clinical Research; Clinical Trials; Collaborations; Commit; Community Clinical Oncology Program; Community Outreach; Complex; Comprehensive Cancer Center; Conquest; Core Facility; Defect; Development; Diagnosis; Diagnostic; Diagnostic Imaging; Disease; Disorder by Site; Drug Design; Drug Kinetics; Engineering; Enrollment; Evaluation; Faculty; Financial Support; Flow Cytometry; Fostering; Funding; Genomics; Goals; Grant; Head and Neck Cancer; Health Communication; Health system; Hematologic Neoplasms; Heterogeneity; Human; Image; Imaging technology; Immune response; Immunologic Monitoring; Industry; Informatics; Infusion procedures; Institution; Instruction; Investments; Laboratories; Laboratory Research; Leadership; Location; Malignant Neoplasms; Medical center; Medicine; Minority; Mission; Modeling; Molecular; Molecular Target; Morphology; NCI Center for Cancer Research; Neoplasm Circulating Cells; New Agents; Patients; Pharmacy facility; Phase; Phase I Clinical Trials; Population Sciences; Positioning Attribute; Prevention; Prevention program; Process; Productivity; Prostate; Public Health Dentistry; Publications; Publishing; Radiation; Recruitment Activity; Research; Research Personnel; Resources; Role; Schools; Science; Site; Social Behavior; Solid Neoplasm; Southwest Oncology Group; Staging; Strategic Planning; Testing; Therapeutic; Therapy Clinical Trials; Tissues; Transgenic Mice; Transgenic Model; Translational Research; University of Michigan Comprehensive Cancer Center; Validation; Vision; Xenograft procedure; anticancer research; base; cancer cell; cancer genetics; cancer prevention; cancer research center director; cancer stem cell; cancer therapy; cellular imaging; clinical research site; drug development; genetic analysis; genetic technology; high throughput screening; innovation; irradiation; member; molecular imaging; molecular pathology; mouse model; neoplastic cell; novel; oncology; patient population; phase 1 study; practical application; pre-clinical; programs; research and development; small molecule; structural biology; success; survivorship; therapeutic target; tool; tumor; tumor immunology; vector

DESCRIPTION (provided by applicant): The University of Michigan Comprehensive Cancer Center (UMCCC) requests the sixth renewal of its core grant since the initial NCI award in 1988. Dr. Max Wicha, the founding Director of the Cancer Center, continues to serve as Director, supported by a strong, nationally recognized senior leadership team. The Center provides an organizational framework to promote interdisciplinary cancer research through the development of well-funded basic, clinical and prevention programs in cancer research and the development of shared core resources. The Cancer Center's 13 research programs include six basic research programs in Cancer Genetics, Cancer Cell Biology, Radiation Sciences, Molecular Imaging, Experimental Therapeutics and Tumor Immunology Host Response; five clinical research programs: Hematologic Malignancies/BMT, Breast, Prostate, Gl and Head and Neck cancers; and two prevention programs Biomedical and Sociobehavioral. Support is requested for a total of 18 shared core facilities, including 13 existing cores. Clinical Trials, Biostatistis, Tissue and Molecular Pathology, Tumor Imaging, Morphology, Flow Cytometry, Experimental Irradiation, Transgenic Mouse, Vector, Immune Monitoring, Genomics, Informatics, Health Communications and five new cores: Patient and Population Sciences, High Throughput Screening, Pharmacokinetics, Structural Biology and Xenograft. Funds are also requested for development, senior leadership, planning and evaluation and administration to support center goals. The UMCCC's 337 members have contributed many high impact discoveries over this grant period. The Cancer Center's mission of "the conquest of cancer through innovation and collaboration" is further evidenced by the high degree of intra- (15.6%) and inter- (35.4%) programmatic publications published in this grant period. The UMCCC's success is underscored by its current ranking as #1 in NCI funding among all matrix cancer centers. The Medical Center has continued to make substantial commitments to the Cancer Center in space, financial support and designation of cancers as among its highest priorities for both clinical and research investment. The acquisition of the former Pfizer campus, now called North Campus Research Complex, represents an unparalleled opportunity for cancer discovery over the next grant period.

描述（由申请人提供）：密歇根大学综合癌症中心（UMCCC）申请自1988年NCI初始奖励以来第六次更新其核心资助。癌症中心创始主任Max Wicha博士继续担任主任，由一个强大的，国家认可的高级领导团队提供支持。该中心通过发展资金充足的癌症研究基础、临床和预防项目以及共享核心资源，为促进跨学科癌症研究提供了一个组织框架。癌症中心的13个研究项目包括癌症遗传学、癌细胞生物学、放射科学、分子成像、实验治疗学和肿瘤免疫宿主反应等6个基础研究项目；五个临床研究项目：血液恶性肿瘤/BMT，乳腺癌，前列腺癌，Gl和头颈部癌症；以及两个预防项目生物医学和社会行为。要求为总共18个共享核心设施提供支持，其中包括13个现有核心。临床试验、生物统计学、组织与分子病理学、肿瘤影像学、形态学、流式细胞术、实验照射、转基因小鼠、载体、免疫监测、基因组学、信息学、卫生通信和五个新核心：患者与人口科学、高通量筛选、药代动力学、结构生物学和异种移植。还要求为发展、高级领导、规划、评估和管理提供资金，以支持中心的目标。